Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport, M Aapro, MR Chasen… - Drug Design …, 2017 - Taylor & Francis
Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
[PDF][PDF] Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport - Drug Design, Development and Therapy, 2017 - academia.edu
Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
[HTML][HTML] Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport, M Aapro, MR Chasen… - Drug Design …, 2017 - ncbi.nlm.nih.gov
Abstract Knowledge of the involvement of the neurokinin substance P in emesis has led to
the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
[PDF][PDF] Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport - Drug Design, Development and Therapy, 2017 - scienceopen.com
Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
BL Rapoport, M Aapro, MR Chasen… - Drug Design …, 2017 - europepmc.org
Abstract Knowledge of the involvement of the neurokinin substance P in emesis has led to
the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
[PDF][PDF] Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport - Drug Design, Development and Therapy, 2017 - pdfs.semanticscholar.org
Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
[PDF][PDF] Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport - Drug Design, Development and Therapy, 2017 - core.ac.uk
Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport, M Aapro, MR Chasen, K Jordan… - Drug Design …, 2017 - go.gale.com
Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport, M Aapro, MR Chasen… - Drug Design …, 2017 - search.proquest.com
Abstract Knowledge of the involvement of the neurokinin substance P in emesis has led to
the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
BL Rapoport, M Aapro, MR Chasen… - Drug design …, 2017 - pubmed.ncbi.nlm.nih.gov
Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …